We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
348 result(s) found, displaying 1 to 10
-
Oct-2025Prescription medicine evaluationActive ingredient: pembrolizumab.
-
Australian public assessment report (AusPar)Capvaxive is indicated for active immunisation for the prevention of pneumococcal disease caused by Streptococcus pneumoniae serotypes (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B) in adults 18 years of age and older.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for WELIREG belzutifan 40 mg film-coated tablet blister pack.
-
Australian public assessment report (AusPar)Winrevair (sotatercept) has been approved for the treatment of adults with pulmonary arterial hypertension (PAH) in WHO Functional Class (FC) II or III, in combination with standard therapy.
-
Prescription medicine registrationActive ingredients: pembrolizumab.
-
Prescription medicine registrationActive ingredients: pembrolizumab.
-
Jun-2025Prescription medicine evaluationActive ingredient: sotatercept.
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd